chordoma
Conditions
Interventions
Experimental Group:Anlotinib (Forcovi , 10mg, d1-14 per cycle, po)
TQB2450 (1200 mg on day 1 per cycle, iv). Every 21 days (3 weeks) was a cycle. Until disease progression or intolerable toxicity.
Sponsors
Shanghai General Hospital, Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with histologically confirmed chordoma who underwent X-ray, CT or magnetic resonance imaging; 2. VEGFR/PDGFR/FGFR+ and PD-L1+ confirmed by immunohistochemistry (TC (VEGFR/PDGFR/FGFR) score >=50% and CPS (PD-L1) score >=1); 3. Patients with proven advanced chordoma who cannot benefit from surgery or radiotherapy; 4. Good functional status (hemoglobin >=9 g/dL) and ECOG performance status 0-1; 5. The expected survival time is more than 6 months; 6. Measurable lesions (RECIST 1.1); 7. Aged 18-75 years.
Exclusion criteria
Exclusion criteria: 1. A history of severe mental illness, such as bipolar disorder or mental illness, that can affect clinical assessment parameters; 2. Patients who have received other multi-target anti-angiogenic drugs and/or immunotherapy in the past, or who are allergic to the active ingredients and excipients of relevant therapeutic drugs; 3. The patient failed to follow up for at least 6 months as instructed by the doctor; 4. Currently participating in an interventional clinical study, or receiving other investigational drugs or using investigational devices within 4 weeks prior to initial dosing; 5. Received major surgical treatment (except surgery for biopsy) within 2-4 weeks of drug administration in the first study; 6. Multiple factors affecting oral medication (such as inability to swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal obstruction); 7. Other groups not suitable to participate in intervention studies, such as pregnant patients, patients with multiple tumors, and patients with severe liver and kidney dysfunction who cannot tolerate treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;disease control rate;overall survival;symptoms and living conditions;assessments of safety; | — |
Countries
China
Contacts
Public ContactMeng Tong
Shanghai General Hospital, Shanghai Jiaotong University
Outcome results
None listed